Association of DNA damage response (DDR) gene mutations (mts) and response to neoadjuvant cisplatin-based chemotherapy (chemo) in muscle-invasive bladder cancer (MIBC) patients (pts) enrolled onto SWOG S1314.

被引：0
|
作者：
Iyer, Gopa
Tangen, Catherine
Sarfaty, Michal
Regazzi, Ashley Marie
Lee, I-Ling C.
Choi, Woonyoung
Dinney, Colin P. N.
Flaig, Thomas W.
Thompson, Ian M.
McConkey, David James
Rosenberg, Jonathan E.
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Fred Hutchinson Canc Res Ctr, Seattle, WA USA
[3] Davidoff Canc Ctr, Rabin Med Ctr, Petah Tiqwa, Israel
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[5] Johns Hopkins, Johns Hopkins Greenberg Bladder Can Inst, Dept Urol, Baltimore, MD USA
[6] Univ Colorado, Canc Ctr, Aurora, CO USA
[7] Childrens Hosp San Antonio, San Antonio, TX USA
[8] Johns Hopkins Greenberg Bladder Canc Inst, Baltimore, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4522
引用
收藏
页数：1
相关论文
共 50 条
  • [41] DNA damage repair (DDR) gene mutations (mut) are predictors of response to platinum-based chemotherapy in advanced pancreatic cancer (PC) patients (pts)
    Verdaguer, H.
    Guardiola, M.
    Mancuso, F. M.
    Acosta Eyzaguirre, D. A.
    Buxo, E.
    Hernando, J.
    Diez Garcia, M.
    Laquente, B.
    Baraibar Argota, I.
    Ros Montana, F. J.
    Garcia-Alvarez, A.
    Matito, J.
    Martin, A.
    Sierra, A.
    Villacampa Javierre, G.
    Molero, C.
    Miquel, J. M.
    Vivancos, A.
    Dienstmann, R.
    Macarulla Mercade, T.
    ANNALS OF ONCOLOGY, 2020, 31 : S947 - S947
  • [42] Predictors of Response Following Neoadjuvant Cisplatin-Based Chemotherapy for Muscle Invasive Urothelial Bladder Cancer Using Molecular Profile: A Prospective Clinical Study
    Elkarta, Ahmed
    Awadalla, Amira
    El-hefnawy, Ahmed
    Mosbah, Ahmed
    Abolenein, Hassan
    Shokeir, Ahmed
    CLINICAL GENITOURINARY CANCER, 2024, 22 (02) : 38 - 46.e1
  • [43] Potential role of a clinical, taxonomical classification and RNA expression integrated signature to predict response to neoadjuvant platinum-based chemotherapy in muscle-invasive bladder cancer (MIBC) patients
    Font, A.
    Domenech, M.
    Ramirez, J. L.
    Gago, J.
    Carrato, C.
    Cadenas, B.
    Benitez, R.
    Lobato, T.
    Pineda, S.
    Ruiz de Porras, V.
    Calle, M. L.
    Malats, N.
    Real, F. X.
    ANNALS OF ONCOLOGY, 2019, 30
  • [44] Potential role of a clinical, taxonomical classification and RNA expression integrated signature to predict response to neoadjuvant platinum-based chemotherapy in Muscle-Invasive Bladder Cancer (MIBC) patients
    Gago, Ramos J. L.
    Font, A.
    Domenech, M.
    Carrato, C.
    Ramirez, J. L.
    Cadenas, B.
    Calle, M.
    Malats, N.
    Real, F. X.
    EUROPEAN UROLOGY, 2021, 79 : S634 - S634
  • [45] Using radiologic response to predict prognosis in patients with muscle-invasive bladder cancer undergoing carboplatin-based neoadjuvant chemotherapy
    Hatakeyama, Shingo
    Yamamoto, Hayato
    Okamoto, Akiko
    Imai, Atsushi
    Yoneyama, Takahiro
    Hashimoto, Yasuhiro
    Koie, Takuya
    Ohyama, Chikara
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [46] KEYNOTE-866: Phase III study of perioperative pembrolizumab (pembro) or placebo (pbo) in combination with neoadjuvant chemotherapy in cisplatin (cis)-eligible patients (pts) with muscle-invasive bladder cancer (MIBC)
    Siefker-Radtke, A. O.
    Steinberg, G.
    Bedke, J.
    Nishiyama, H.
    Martin, J.
    Kataria, R.
    Frenkl, T. L.
    Hoimes, C. J.
    ANNALS OF ONCOLOGY, 2019, 30 : 401 - 401
  • [47] TAR-200 plus cetrelimab (CET) or CET alone as neoadjuvant therapy in patients (pts) with muscle-invasive bladder cancer (MIBC) who are ineligible for or refuse neoadjuvant cisplatin-based chemotherapy (NAC): Interim analysis of SunRISe-4 (SR-4)
    Necchi, A.
    Guerrero-Ramos, F.
    Crispen, P. L.
    Imbroda, B. Herrera
    Garje, R.
    Powles, T. B.
    Peyton, C. C.
    Pradere, B.
    Ku, J. H.
    Shore, N. D.
    Boegemann, M.
    Preston, M. A.
    Xylinas, E.
    Gong, C.
    Najmi, S.
    Hasan, M.
    Stitou, H.
    Bhanvadia, S.
    Sweiti, H.
    Psutka, S. P.
    ANNALS OF ONCOLOGY, 2024, 35 : 1271 - 1272
  • [48] Cell-Free Urine and Plasma DNA Mutational Analysis Predicts Neoadjuvant Chemotherapy Response and Outcome in Patients with Muscle-Invasive Bladder Cancer
    Christensen, Emil
    Nordentoft, Iver
    Birkenkamp-Demtroder, Karin
    Elbaek, Sara K.
    Lindskrog, Sia, V
    Taber, Ann
    Andreasen, Tine G.
    Strandgaard, Trine
    Knudsen, Michael
    Lamy, Philippe
    Agerbaek, Mads
    Jensen, Jorgen B.
    Dyrskjot, Lars
    CLINICAL CANCER RESEARCH, 2023, 29 (08) : 1582 - 1591
  • [49] Immunohistochemical based molecular subtypes of muscle-invasive bladder cancer: association with HER2 and EGFR alterations, neoadjuvant chemotherapy response and survival
    Duaa S. Helal
    Sara A. Darwish
    Radwa A. Awad
    Dina A. Ali
    Dina M. El-Guindy
    Diagnostic Pathology, 18
  • [50] Immunohistochemical based molecular subtypes of muscle-invasive bladder cancer: association with HER2 and EGFR alterations, neoadjuvant chemotherapy response and survival
    Helal, Duaa S. S.
    Darwish, Sara A. A.
    Awad, Radwa A. A.
    Ali, Dina A. A.
    El-Guindy, Dina M. M.
    DIAGNOSTIC PATHOLOGY, 2023, 18 (01)
12345